View Future GrowthMedicalgorithmics 過去の業績過去 基準チェック /06Medicalgorithmicsの収益は年間平均-25.2%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間6.4% 26.1%割合で 減少しています。主要情報-25.19%収益成長率-7.75%EPS成長率Medical Equipment 業界の成長25.29%収益成長率-26.07%株主資本利益率-18.07%ネット・マージン-37.71%次回の業績アップデート28 May 2026最近の業績更新Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.お知らせ • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.お知らせ • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).すべての更新を表示Recent updatesPrice Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.Buy Or Sell Opportunity • Apr 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to zł26.10. The fair value is estimated to be zł32.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 75% in a year. Earnings are forecast to grow by 84% in the next year.分析記事 • Apr 17At zł28.35, Is Medicalgorithmics S.A. (WSE:MDG) Worth Looking At Closely?Medicalgorithmics S.A. ( WSE:MDG ), is not the largest company out there, but it saw a decent share price growth of 11...Buy Or Sell Opportunity • Mar 31Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to zł27.85. The fair value is estimated to be zł34.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 88% in a year. Earnings are forecast to grow by 89% in the next year.Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.お知らせ • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025Buy Or Sell Opportunity • Nov 06Now 22% overvaluedOver the last 90 days, the stock has fallen 5.5% to zł31.95. The fair value is estimated to be zł26.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.Buy Or Sell Opportunity • Oct 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 10% to zł34.50. The fair value is estimated to be zł27.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.分析記事 • Oct 11A Look At The Intrinsic Value Of Medicalgorithmics S.A. (WSE:MDG)Key Insights Medicalgorithmics' estimated fair value is zł33.99 based on 2 Stage Free Cash Flow to Equity Current share...New Risk • Oct 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł354.3m (US$96.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Sep 08Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 64% to zł41.70. The fair value is estimated to be zł34.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 64%. Revenue is forecast to grow by 72% in a year. Earnings are forecast to grow by 50% in the next year.分析記事 • Sep 08Would Medicalgorithmics (WSE:MDG) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025分析記事 • Aug 15What Is Medicalgorithmics S.A.'s (WSE:MDG) Share Price Doing?WSE:MDG 1 Year Share Price vs Fair Value Explore Medicalgorithmics's Fair Values from the Community and select yours...Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.お知らせ • May 20Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025.New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Market cap is less than US$100m (zł225.1m market cap, or US$55.7m).Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).Reported Earnings • Oct 02Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł5.91m (down 39% from 2Q 2023). Net loss: zł5.32m (loss widened 328% from 2Q 2023).Reported Earnings • Jun 04First quarter 2024 earnings released: zł0.40 loss per share (vs zł0.15 profit in 1Q 2023)First quarter 2024 results: zł0.40 loss per share (down from zł0.15 profit in 1Q 2023). Revenue: zł7.02m (down 38% from 1Q 2023). Net loss: zł4.01m (down 364% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • May 18Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024.Reported Earnings • Apr 24Full year 2023 earnings released: zł0.06 loss per share (vs zł3.17 profit in FY 2022)Full year 2023 results: zł0.06 loss per share (down from zł3.17 profit in FY 2022). Revenue: zł43.1m (down 31% from FY 2022). Net loss: zł578.0k (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jan 30+ 3 more updatesMedicalgorithmics S.A. to Report Fiscal Year 2023 Results on Apr 22, 2024Medicalgorithmics S.A. announced that they will report fiscal year 2023 results on Apr 22, 2024Reported Earnings • Dec 03Third quarter 2023 earnings released: zł0.019 loss per share (vs zł0.93 profit in 3Q 2022)Third quarter 2023 results: zł0.019 loss per share (down from zł0.93 profit in 3Q 2022). Revenue: zł9.57m (down 45% from 3Q 2022). Net loss: zł178.0k (down 104% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.90, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 12x in the Medical Equipment industry in Poland. Total returns to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł32.45, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 11x in the Medical Equipment industry in Poland. Total returns to shareholders of 52% over the past three years.分析記事 • Sep 20Is Medicalgorithmics (WSE:MDG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to zł36.50, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 15x in the Medical Equipment industry in Poland. Total returns to shareholders of 33% over the past three years.Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł27.35, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 14x in the Medical Equipment industry in Poland. Total returns to shareholders of 5.0% over the past three years.New Risk • Jul 03New major risk - Revenue and earnings growthEarnings have declined by 62% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł231.9m market cap, or US$56.9m).分析記事 • Jun 14These 4 Measures Indicate That Medicalgorithmics (WSE:MDG) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł21.85, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 7x in the Medical Equipment industry in Poland. Total loss to shareholders of 15% over the past three years.お知らせ • Jun 13Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023, at 14:00 Central European Standard Time.Reported Earnings • Jun 04First quarter 2023 earnings released: EPS: zł0.15 (vs zł11.14 loss in 1Q 2022)First quarter 2023 results: EPS: zł0.15 (up from zł11.14 loss in 1Q 2022). Revenue: zł11.3m (down 61% from 1Q 2022). Net income: zł1.52m (up zł57.0m from 1Q 2022). Profit margin: 14% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.分析記事 • May 04Medicalgorithmics (WSE:MDG) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Medicalgorithmics S.A.'s ( WSE:MDG ) shareholders. Our analysis...お知らせ • Jan 26+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2023 Results on Nov 29, 2023Medicalgorithmics S.A. announced that they will report Q3, 2023 results on Nov 29, 2023Reported Earnings • Dec 02Third quarter 2022 earnings released: EPS: zł5.51 (vs zł0.31 loss in 3Q 2021)Third quarter 2022 results: EPS: zł5.51 (up from zł0.31 loss in 3Q 2021). Revenue: zł17.4m (down 43% from 3Q 2021). Net income: zł4.63m (up zł5.98m from 3Q 2021). Profit margin: 27% (up from net loss in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.お知らせ • Oct 05Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million.Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million on October 3, 2022. Bio Fund to also provide company with additional financing of up to $2.8 million (PLN 13.8 million) over three year period from share purchase.Reported Earnings • Sep 30Second quarter 2022 earnings released: EPS: zł1.39 (vs zł0.43 loss in 2Q 2021)Second quarter 2022 results: EPS: zł1.39 (up from zł0.43 loss in 2Q 2021). Revenue: zł35.5m (up 28% from 2Q 2021). Net income: zł6.93m (up zł8.79m from 2Q 2021). Profit margin: 20% (up from net loss in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.お知らせ • Aug 11Medicalgorithmics S.A. Secures FDA Approval for DeepRhytmAI TechnologyMedicalgorithmics S.A. has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI. It is a cloud-based Artificial Intelligence algorithm that classifies ECG signals. Without excessive human involvement, DeepRhytmAI is able to recognize a wide range of arrhythmia disorders for a more quick and accurate patient diagnosis. DeepRhytmAI is designed for use with the Company's devices but can be integrated with solutions of other providers, as well. Based on the Company's data, once DeepRhytmAI is integrated with the next generation of PocketECG system (under development) it could cut down the work needed to classify ECG signal by about 50%. DeepRhytmAI will be accessible to business partners who use its devices together with the next generation PocketECG system not earlier than in the second half of 2023. Medicalgorithmics operates in the industry of advanced telemetry for medicine. The Group provides solutions for cardiac diagnostics, especially in the area of ECG signal analysis. Its services are available in several countries and continents of the world, including North America, Asia, Europe and Australia.お知らせ • Jun 07Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022, at 09:00 Central European Standard Time.分析記事 • Mar 09Is Medicalgorithmics (WSE:MDG) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Feb 01+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2022 Results on Nov 29, 2022Medicalgorithmics S.A. announced that they will report Q3, 2022 results on Nov 29, 2022お知らせ • Jan 22Rafal Brzoska Withdrawn from Negotiations with MedicalgorithmicsMedicalgorithmics S.A. (WSE:MDG) said on January 20, 2022 Rafal Brzoska (investor) has withdrawn from negotiations regarding purchase of company's stake. The investor said the business conditions of the deal, as well as the current economic cycle and increased variability of financial markets do not provide sufficient reasons for carrying out a potential transaction. The company continues strategic options review.Reported Earnings • Nov 17Third quarter 2021 earnings released: zł0.31 loss per share (vs zł0.80 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: zł30.6m (up 22% from 3Q 2020). Net loss: zł1.36m (loss narrowed 61% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 03Second quarter 2021 earnings released: zł0.43 loss per share (vs zł0.33 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł27.7m (up 20% from 2Q 2020). Net loss: zł1.85m (loss widened 55% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Reported Earnings • May 28First quarter 2021 earnings released: zł0.23 loss per share (vs zł0.91 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: zł31.4m (down 13% from 1Q 2020). Net loss: zł1.01m (loss narrowed 69% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 04Full year 2020 earnings released: zł3.12 loss per share (vs zł1.19 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: zł111.7m (down 36% from FY 2019). Net loss: zł12.9m (down 402% from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Feb 15New 90-day high: zł25.50The company is up 2.0% from its price of zł24.95 on 17 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 20% over the same period.お知らせ • Jan 29+ 3 more updatesMedicalgorithmics S.A. to Report Q1, 2021 Results on May 25, 2021Medicalgorithmics S.A. announced that they will report Q1, 2021 results on May 25, 2021Reported Earnings • Nov 26Third quarter 2020 earnings released: zł0.80 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: zł25.1m (down 41% from 3Q 2019). Net loss: zł3.44m (down zł3.52m from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 91% per year but the company’s share price has only fallen by 53% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 29New 90-day low: zł19.98The company is down 23% from its price of zł26.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 68% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: zł21.00The company is down 17% from its price of zł25.30 on 15 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 194% over the same period.収支内訳Medicalgorithmics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史WSE:MDG 収益、費用、利益 ( )PLN Millions日付収益収益G+A経費研究開発費31 Dec 2531-1219030 Sep 2527-1518030 Jun 2525-1316031 Mar 2524-1615031 Dec 2424-1616030 Sep 2431-1216030 Jun 2435-1015031 Mar 2439-615031 Dec 2343-113030 Sep 2349814030 Jun 23571314031 Mar 23612513031 Dec 22632512030 Sep 2259111030 Jun 2253-39031 Mar 2230-43031 Dec 2148-79030 Sep 2161413030 Jun 2175118031 Mar 21107-1130031 Dec 20112-1330030 Sep 20122-1032030 Jun 20139-633031 Mar 20161-336031 Dec 19174436030 Sep 191931236030 Jun 192001437031 Mar 192041534031 Dec 181991432030 Sep 181931628030 Jun 181952226031 Mar 182062827031 Dec 172032628030 Sep 171884930030 Jun 171784534031 Mar 171554833031 Dec 161284041030 Sep 161071037030 Jun 1679831031 Mar 1653327031 Dec 15491412030 Sep 1544168030 Jun 15401750質の高い収益: MDGは現在利益が出ていません。利益率の向上: MDGは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MDGは利益が出ておらず、過去 5 年間で損失は年間25.2%の割合で増加しています。成長の加速: MDGの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MDGは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 2.5% ) と比較することは困難です。株主資本利益率高いROE: MDGは現在利益が出ていないため、自己資本利益率 ( -18.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:32終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medicalgorithmics S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Adrian KowollikEast Value Research GmbHLukasz KosiarskiIpopema Securities S.A.Gabriela BurdachWood & Company
Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025
Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025
Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.
Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).
Price Target Changed • May 19Price target decreased by 7.2% to zł41.35Down from zł44.55, the current price target is an average from 2 analysts. New target price is 40% above last closing price of zł29.60. Stock is up 5.7% over the past year. The company is forecast to post a net loss per share of zł0.20 next year compared to a net loss per share of zł1.17 last year.
Buy Or Sell Opportunity • Apr 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to zł26.10. The fair value is estimated to be zł32.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 75% in a year. Earnings are forecast to grow by 84% in the next year.
分析記事 • Apr 17At zł28.35, Is Medicalgorithmics S.A. (WSE:MDG) Worth Looking At Closely?Medicalgorithmics S.A. ( WSE:MDG ), is not the largest company out there, but it saw a decent share price growth of 11...
Buy Or Sell Opportunity • Mar 31Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to zł27.85. The fair value is estimated to be zł34.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 36% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 88% in a year. Earnings are forecast to grow by 89% in the next year.
Reported Earnings • Nov 09Third quarter 2025 earnings released: zł0.41 loss per share (vs zł0.21 loss in 3Q 2024)Third quarter 2025 results: zł0.41 loss per share (further deteriorated from zł0.21 loss in 3Q 2024). Revenue: zł7.19m (up 38% from 3Q 2024). Net loss: zł4.06m (loss widened 91% from 3Q 2024). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 06Medicalgorithmics S.A. to Report Q3, 2025 Results on Nov 06, 2025Medicalgorithmics S.A. announced that they will report Q3, 2025 results on Nov 06, 2025
Buy Or Sell Opportunity • Nov 06Now 22% overvaluedOver the last 90 days, the stock has fallen 5.5% to zł31.95. The fair value is estimated to be zł26.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.
Buy Or Sell Opportunity • Oct 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 10% to zł34.50. The fair value is estimated to be zł27.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 33% over the last 3 years. Earnings per share has declined by 89%. Revenue is forecast to grow by 76% in a year. Earnings are forecast to grow by 60% in the next year.
分析記事 • Oct 11A Look At The Intrinsic Value Of Medicalgorithmics S.A. (WSE:MDG)Key Insights Medicalgorithmics' estimated fair value is zł33.99 based on 2 Stage Free Cash Flow to Equity Current share...
New Risk • Oct 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł354.3m (US$96.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 02Second quarter 2025 earnings released: zł0.25 loss per share (vs zł0.53 loss in 2Q 2024)Second quarter 2025 results: zł0.25 loss per share (improved from zł0.53 loss in 2Q 2024). Revenue: zł6.97m (up 18% from 2Q 2024). Net loss: zł2.49m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 139 percentage points per year, which is a significant difference in performance.
New Risk • Sep 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Sep 08Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 64% to zł41.70. The fair value is estimated to be zł34.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has declined by 64%. Revenue is forecast to grow by 72% in a year. Earnings are forecast to grow by 50% in the next year.
分析記事 • Sep 08Would Medicalgorithmics (WSE:MDG) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Aug 25Medicalgorithmics S.A. to Report First Half, 2025 Results on Sep 30, 2025Medicalgorithmics S.A. announced that they will report first half, 2025 results on Sep 30, 2025
分析記事 • Aug 15What Is Medicalgorithmics S.A.'s (WSE:MDG) Share Price Doing?WSE:MDG 1 Year Share Price vs Fair Value Explore Medicalgorithmics's Fair Values from the Community and select yours...
Reported Earnings • Jun 04First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: zł6.77m (down 3.5% from 1Q 2024). Net loss: zł4.20m (loss widened 4.8% from 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Europe.
お知らせ • May 20Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025Medicalgorithmics S.A., Annual General Meeting, Jun 17, 2025.
New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Market cap is less than US$100m (zł225.1m market cap, or US$55.7m).
Reported Earnings • Dec 01Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł5.21m (down 46% from 3Q 2023). Net loss: zł2.13m (loss widened zł1.95m from 3Q 2023).
Reported Earnings • Oct 02Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł5.91m (down 39% from 2Q 2023). Net loss: zł5.32m (loss widened 328% from 2Q 2023).
Reported Earnings • Jun 04First quarter 2024 earnings released: zł0.40 loss per share (vs zł0.15 profit in 1Q 2023)First quarter 2024 results: zł0.40 loss per share (down from zł0.15 profit in 1Q 2023). Revenue: zł7.02m (down 38% from 1Q 2023). Net loss: zł4.01m (down 364% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • May 18Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024Medicalgorithmics S.A., Annual General Meeting, Jun 12, 2024.
Reported Earnings • Apr 24Full year 2023 earnings released: zł0.06 loss per share (vs zł3.17 profit in FY 2022)Full year 2023 results: zł0.06 loss per share (down from zł3.17 profit in FY 2022). Revenue: zł43.1m (down 31% from FY 2022). Net loss: zł578.0k (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jan 30+ 3 more updatesMedicalgorithmics S.A. to Report Fiscal Year 2023 Results on Apr 22, 2024Medicalgorithmics S.A. announced that they will report fiscal year 2023 results on Apr 22, 2024
Reported Earnings • Dec 03Third quarter 2023 earnings released: zł0.019 loss per share (vs zł0.93 profit in 3Q 2022)Third quarter 2023 results: zł0.019 loss per share (down from zł0.93 profit in 3Q 2022). Revenue: zł9.57m (down 45% from 3Q 2022). Net loss: zł178.0k (down 104% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł25.90, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 12x in the Medical Equipment industry in Poland. Total returns to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł32.45, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 11x in the Medical Equipment industry in Poland. Total returns to shareholders of 52% over the past three years.
分析記事 • Sep 20Is Medicalgorithmics (WSE:MDG) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Aug 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to zł36.50, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 15x in the Medical Equipment industry in Poland. Total returns to shareholders of 33% over the past three years.
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to zł27.35, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 14x in the Medical Equipment industry in Poland. Total returns to shareholders of 5.0% over the past three years.
New Risk • Jul 03New major risk - Revenue and earnings growthEarnings have declined by 62% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. High level of non-cash earnings (48% accrual ratio). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (zł231.9m market cap, or US$56.9m).
分析記事 • Jun 14These 4 Measures Indicate That Medicalgorithmics (WSE:MDG) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł21.85, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 7x in the Medical Equipment industry in Poland. Total loss to shareholders of 15% over the past three years.
お知らせ • Jun 13Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2023, at 14:00 Central European Standard Time.
Reported Earnings • Jun 04First quarter 2023 earnings released: EPS: zł0.15 (vs zł11.14 loss in 1Q 2022)First quarter 2023 results: EPS: zł0.15 (up from zł11.14 loss in 1Q 2022). Revenue: zł11.3m (down 61% from 1Q 2022). Net income: zł1.52m (up zł57.0m from 1Q 2022). Profit margin: 14% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
分析記事 • May 04Medicalgorithmics (WSE:MDG) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Medicalgorithmics S.A.'s ( WSE:MDG ) shareholders. Our analysis...
お知らせ • Jan 26+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2023 Results on Nov 29, 2023Medicalgorithmics S.A. announced that they will report Q3, 2023 results on Nov 29, 2023
Reported Earnings • Dec 02Third quarter 2022 earnings released: EPS: zł5.51 (vs zł0.31 loss in 3Q 2021)Third quarter 2022 results: EPS: zł5.51 (up from zł0.31 loss in 3Q 2021). Revenue: zł17.4m (down 43% from 3Q 2021). Net income: zł4.63m (up zł5.98m from 3Q 2021). Profit margin: 27% (up from net loss in 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 05Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million.Bio Fund Management Ltd. signed an agreement to acquire 100% stake in Kardiolytics Inc. for $44.9 million on October 3, 2022. Bio Fund to also provide company with additional financing of up to $2.8 million (PLN 13.8 million) over three year period from share purchase.
Reported Earnings • Sep 30Second quarter 2022 earnings released: EPS: zł1.39 (vs zł0.43 loss in 2Q 2021)Second quarter 2022 results: EPS: zł1.39 (up from zł0.43 loss in 2Q 2021). Revenue: zł35.5m (up 28% from 2Q 2021). Net income: zł6.93m (up zł8.79m from 2Q 2021). Profit margin: 20% (up from net loss in 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 11Medicalgorithmics S.A. Secures FDA Approval for DeepRhytmAI TechnologyMedicalgorithmics S.A. has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI. It is a cloud-based Artificial Intelligence algorithm that classifies ECG signals. Without excessive human involvement, DeepRhytmAI is able to recognize a wide range of arrhythmia disorders for a more quick and accurate patient diagnosis. DeepRhytmAI is designed for use with the Company's devices but can be integrated with solutions of other providers, as well. Based on the Company's data, once DeepRhytmAI is integrated with the next generation of PocketECG system (under development) it could cut down the work needed to classify ECG signal by about 50%. DeepRhytmAI will be accessible to business partners who use its devices together with the next generation PocketECG system not earlier than in the second half of 2023. Medicalgorithmics operates in the industry of advanced telemetry for medicine. The Group provides solutions for cardiac diagnostics, especially in the area of ECG signal analysis. Its services are available in several countries and continents of the world, including North America, Asia, Europe and Australia.
お知らせ • Jun 07Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022Medicalgorithmics S.A., Annual General Meeting, Jun 30, 2022, at 09:00 Central European Standard Time.
分析記事 • Mar 09Is Medicalgorithmics (WSE:MDG) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Feb 01+ 3 more updatesMedicalgorithmics S.A. to Report Q3, 2022 Results on Nov 29, 2022Medicalgorithmics S.A. announced that they will report Q3, 2022 results on Nov 29, 2022
お知らせ • Jan 22Rafal Brzoska Withdrawn from Negotiations with MedicalgorithmicsMedicalgorithmics S.A. (WSE:MDG) said on January 20, 2022 Rafal Brzoska (investor) has withdrawn from negotiations regarding purchase of company's stake. The investor said the business conditions of the deal, as well as the current economic cycle and increased variability of financial markets do not provide sufficient reasons for carrying out a potential transaction. The company continues strategic options review.
Reported Earnings • Nov 17Third quarter 2021 earnings released: zł0.31 loss per share (vs zł0.80 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: zł30.6m (up 22% from 3Q 2020). Net loss: zł1.36m (loss narrowed 61% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 03Second quarter 2021 earnings released: zł0.43 loss per share (vs zł0.33 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: zł27.7m (up 20% from 2Q 2020). Net loss: zł1.85m (loss widened 55% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 28First quarter 2021 earnings released: zł0.23 loss per share (vs zł0.91 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: zł31.4m (down 13% from 1Q 2020). Net loss: zł1.01m (loss narrowed 69% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 04Full year 2020 earnings released: zł3.12 loss per share (vs zł1.19 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: zł111.7m (down 36% from FY 2019). Net loss: zł12.9m (down 402% from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Feb 15New 90-day high: zł25.50The company is up 2.0% from its price of zł24.95 on 17 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 20% over the same period.
お知らせ • Jan 29+ 3 more updatesMedicalgorithmics S.A. to Report Q1, 2021 Results on May 25, 2021Medicalgorithmics S.A. announced that they will report Q1, 2021 results on May 25, 2021
Reported Earnings • Nov 26Third quarter 2020 earnings released: zł0.80 loss per shareThe company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2020 results: Revenue: zł25.1m (down 41% from 3Q 2019). Net loss: zł3.44m (down zł3.52m from profit in 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 91% per year but the company’s share price has only fallen by 53% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 29New 90-day low: zł19.98The company is down 23% from its price of zł26.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 68% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: zł21.00The company is down 17% from its price of zł25.30 on 15 July 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 194% over the same period.